$TEVA

Teva Pharmaceutical Industries Ltd. (TEVA) plans to issue EUR and USD-denominated senior notes through its subsidiaries. Proceeds will fund redemptions of certain existing notes, pay related fees, and for general corporate purposes, including debt repayment. The offering is subject to market conditions and not conditioned on the redemptions.

President Trump secured drug pricing agreements with nine pharma firms, including Alcon, Astellas, Teva, and UCB, bringing the total to 26 firms representing 90% of the US market. The deals require Medicaid discounts and $19.6B in US manufacturing investments. The White House estimates $529B in economic savings over a decade.

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

Russia reportedly struck a Teva pharmaceutical facility and a WHO warehouse in Ukraine, according to the Kyiv Post. The attack is part of ongoing hostilities, potentially escalating the conflict and affecting market perceptions of a ceasefire. Current odds for a 2026 ceasefire agreement are at 21.5%, with markets watching for international reactions and diplomatic developments.

Russian drones struck Teva Pharmaceuticals' warehouses in Ukraine on Sept. 3, impacting the company's operations. Teva, listed on NASDAQ at $30.62 per share, is assessing the damage. The attack also hit a WHO medical supplies warehouse. Ukraine's Minister of Agrarian Policy reported significant damage to storage facilities. Teva's revenue grew 21% in 2025 to Hr. 4.65 billion ($103 million).

Teva Pharmaceutical's (TEVA) stock declined despite early-stage positive results from a Phase 2a trial of TEV-408 for celiac disease. Investors were unimpressed due to the lack of later-stage data or a commercialization timeline. The company is focusing on specialty medicines and biosimilars to stabilize growth but faces challenges from debt and generic revenue pressure.

Teva Pharmaceutical Industries' experimental drug TEV-53408 met its main goal in a mid-stage trial, preventing intestinal damage in celiac disease patients. The Phase 2a study showed significant improvement in intestinal health and symptom scores compared to placebo. Teva plans further studies and projects peak sales of $1.5B-$2B for the drug, which targets the IL-15 pathway. The company has a deal with Royalty Pharma for up to $500M in support.

Nine drugmakers (Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, UCB) joined Medicaid pricing deals, covering 89% of branded drug market. Savings estimated at $600B over a decade, per the White House. Medicaid copays likely unchanged. Companies to invest $19.6B in U.S. manufacturing and donate drug ingredients.